Background Many women of childbearing potential take antiepileptic drugs, but the cognitive eff ects of fetal exposure are uncertain. We aimed to assess eff ects of commonly used antiepileptic drugs on cognitive outcomes in children up to 6 years of age.
Introduction
Antiepileptic drugs are among the most common teratogens prescribed to women of childbearing potential. 1 Knowledge of antiepileptic drug teratogenicity has increased in the past decade, including a concern that valproate is associated with impaired cognitive outcomes. 2, 3 Based largely on our previously published analysis 3 of outcomes at 3 years of age, the US Food and Drug Administration issued a warning that fetal valproate exposure is associated with impaired cognitive outcomes. 4 In this study, our primary aim was to determine how fetal exposure to diff erent antiepileptic drugs aff ect intelligence quotient (IQ) at 6 years of age (age-6 IQ). Compared with measurements done at younger ages, age-6 IQ is a more stable measure, more strongly related to adult IQ, and more predictive of school performance. 5 Thus, understanding whether diff erences at 3 years of age persist to 6 years is important. In addition, we present a more comprehensive assessment of other cognitive domains than can be assessed at younger ages, and test the hypothesis that antiepileptic drugs can change cerebral lateralisation.
Methods

Study design and participants
The Neurodevelopmental Eff ects of Antiepileptic Drugs (NEAD) study was a prospective observational investigation with masked cognitive assessment. We enrolled pregnant women with epilepsy who were receiving antiepileptic drug monotherapy (ie, carbamazepine, lamotrigine, phenytoin, or valproate) between October, 1999, and February, 2004, from 25 epilepsy centres in the UK and the USA. No other antiepileptic drugs were used in adequate numbers to include in the assessments. We excluded women treated with polytherapy because of its association with worse outcomes compared with monotherapy. 2 A non-exposed control group was not included because the US National Institutes of Health review panel unanimously recommended its deletion from our original design.
Each site's institutional review boards approved the study. Written informed consent was obtained according to the Declaration of Helsinki. A data safety monitoring board appointed by the US National Institutes of Health monitored study conduct. We excluded women with IQ scores of less than 70 to avoid fl oor eff ects because maternal IQ is the major predictor of child IQ. 5 Other exclusions were positive syphilis or HIV serology, progressive cerebral disease, other major disease (eg, diabetes), exposure to known teratogenic drugs other than antiepileptic drugs, poor compliance to antiepileptic drugs, drug misuse in the previous year, or sequelae of drug misuse.
Procedures
We assessed potentially confounding variables ( notably, the dose range for phenytoin was smaller, which could limit sensitivity of analyses for dose eff ects. ¶Therapeutic doses (mg per day) vary between antiepileptic drugs, so doses were standardised to allow comparisons between drugs; ranges within each antiepileptic drug and total-enrolled group were used in the calculation 100 × (observed dose -minimum dose) ÷ range of doses (ie, maximum -minimum). 3 ||Mean gestational age at enrolment was 18 weeks (range 1-38), which did not diff er between antiepileptic drugs. **Any alcohol use during pregnancy (yes vs no). † †Epilepsy types were localisation-related (includes cryptogenic and symptomatic), idiopathic generalised (includes absence, juvenile myoclonic, genetic, and other idiopathic generalised not otherwise classifi ed), and GTCS. ‡ ‡Number (%) of mothers without convulsions or >5 convulsions during pregnancy; seizure frequency during pregnancy was not reported for 14 mothers. 
Statistical analysis
We calculated the sample size on the basis of an 80% power to detect a 0·5 SD diff erence in IQ, which is a clinically meaningful diff erence noted in previous studies. 2 For the primary analysis, we examined group diff erences in IQ in the total-enrolled population (ie, all births). For secondary analyses, we assessed diff erences in IQ in children completing age-6 testing (age-6-completer sample), diff erences across outcomes at 2 years, 3 years, 4·5 years, and 6 years, correlations of age-6 IQ to dose and maternal IQ by antiepileptic drug, and analyses of handedness, verbal or non-verbal abilities, memory, and executive functions. Analyses were done at the NEAD Data and Statistical Centre by NB with SAS and R statistical software.
For the primary analysis, we used linear regression models to examine group diff erences in IQ, adjusting for maternal IQ, antiepileptic drug type, standardised dose, gestational birth age, and use of periconceptional folate. Additional covariates were maternal age, ethnic group, maternal education, epilepsy or seizure types, seizure frequency during pregnancy, employment status, socioeconomic status, site, alcohol or tobacco use, concomitant drug use, birthweight, unwanted pregnancy, breastfeeding, birth defects and complications in present and past pregnancies, and antiepileptic drug compliance (appendix pp [3] [4] .
Because specifi c antiepileptic drug type and dose and maternal IQ are important covariates, we included these variables as predictors in a linear model with child IQ as the outcome. Other covariates were added individually to the model and included if signifi cant (p<0·05) and not colinear with existing predictors. We inspected diagnostic plots to ensure that distributional assumptions of the models were met. For the total-enrolled analysis, we used Markov chain Monte Carlo methods 13, 14 to impute missing outcomes at 6 years of age from available outcomes at 2 years, 3 years, and 4·5 years of age and baseline variables related to outcome or likelihood of missing data. The imputation procedure generated 50 imputed datasets and fi t regression models to each. We combined regression parameter estimates across imputations with standard errors that incorporated imputation uncertainty. The following variables were used in the imputation model: age 2 year, 3 year, and 4·5 year outcomes (BSID and DAS), maternal IQ, antiepileptic drug dose, folate, gestational age, unwanted pregnancy, maternal age, convulsions during pregnancy, employment status, US versus UK site, maternal education, and socioeconomic status. Mothers of children with missing outcomes at 6 years of age diff ered in terms of maternal age and site (the imputation model included these variables). Standard errors and CIs of parameter estimates incorporated imputation uncertainty. We did secondary analyses for age-6-completers without imputation for missing data.
To test the assumption that the proportion of children with lowest cognitive performance (ie, IQ <70 and <85) was unchanged across time, we used Cochran's Q statistic with the sample of children who were tested at all four ages (2 years, 3 years, 4·5 years, and 6 years). We used Fisher's exact test to assess diff erences between antiepileptic drugs in percentages of children with IQ scores of less than 70 and less than 85. We did follow-up analyses to assess the importance of subgroups. We created forest plots to explore whether baseline diff erences explained the association of valproate with poorer cognitive outcomes. We defi ned subgroups by seizure type and propensity scores. Propensity scores are predicted probabilities of receiving a treatment in view of baseline covariates and are used to assess the eff ect of baseline group diff erences (appendix p 12 contains additional details on propensity score analyses).
This study is registered with ClinicalTrials.gov, number NCT00021866.
Role of the funding source
The sponsor of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
Results
We included 305 mothers and 311 livebirths (six twin pairs) in the primary analysis. Table 1 shows baseline maternal characteristics for the total-enrolled sample and appendix p 5 shows maternal characteristics for the age-6-completer sample. We interviewed all mothers about compliance, reviewed all diaries, and assessed antiepileptic drug levels for 229 (75%) mothers. We noted signifi cant associations between antiepileptic drug group and maternal IQ, maternal education, dose, epilepsy type, site, and ethnic group.
Cognitive outcomes were available from at least one test age (ie, BSID at 2 years or DAS IQ at 3 years, 4·5 years, or 6 years) for 279 children (90% of totalenrolled sample). Age-6 IQ correlated with measures at each of the younger ages (appendix p 6). We included 221 mothers (72%) and 225 children (72%; four twin pairs) in the secondary age-6-completer analysis; Figure 1 : Relation between age-6 IQ and standardised dose of every antiepileptic drug during pregnancy Therapeutic dosages (mg per day) vary between antiepileptic drugs, so doses were standardised to allow comparisons; ranges within each antiepileptic drug and total-enrolled group were used in following calculation: 100 × (observed dose -minimum dose) ÷ range of doses (ie, maximum -minimum). 3 Note that this calculation is based on the total-enrolled sample, but scatter plots here depict only the subjects tested at 6 years of age. Correlations are parametric Pearson correlations; non-parametric rank correlations were much the same. Age-6 IQ=IQ score at 6 years of age. IQ=intelligence quotient. however, an IQ score was missing for one mother so 224 children were included in the regression analysis. Mean testing at 6 years of age was at 74 months (range 70-87) and did not diff er between antiepileptic drug type (p=0·99). Scores were standardised for age.
The appendix (p 3) shows the statistical details of totalenrolled and age-6-completer analyses, with additional analyses for paternal and child factors in the appendix table footnote. Independent predictors of child IQ in the total-enrolled sample were antiepileptic drug type (p<0·0001), maternal IQ (p<0·0001), use of periconceptional folate (p=0·0009), standardised dose (p=0·0060), and birth gestational age (p=0·0413). When added to the model, no other variables substantively changed inferences about antiepileptic drug group diff erences. Table 2 lists adjusted mean age-6 IQ scores by antiepileptic drug group for total-enrolled and age-6completer analyses. IQ scores were signifi cantly lower for valproate than they were for the three other antiepileptic drugs. Dose-dependent eff ects were present Figure 3 : Child IQ at 6 years, by exposure to maternal antiepileptic drug use and periconceptional folate Mean (95% CIs) are shown for folate (solid lines) and no folate (dashed lines). For carbamazepine, 56 children were exposed to periconceptional folate (mean IQ 106, 95% CI 102-110) and 38 children were not (103, 98-107); for lamotrigine 60 children were exposed to periconceptional folate (111, 108-115) and 40 children were not (103, 98-107); for phenytoin, 23 children were exposed to periconceptional folate (112, 107-118) and 32 children were not (103, 98-108); for valproate, 40 children were exposed to periconceptional folate (98, 94-103) and 22 children were not (96, 91-102); for all antiepileptic drugs combined, 179 children were exposed to periconceptional folate (107, 105-109) and 132 children were not (102, 99-105). Appendix p 7 shows means and analyses for dose eff ects. IQ=intelligence quotient.
for valproate but not for other antiepileptic drugs (fi gure 1). Linear regression results and correlations were similar with fi rst or third trimester dosages. Child and maternal IQ scores were signifi cantly correlated for all antiepileptic drugs apart from valproate (fi gure 2). Higher child IQ scores were associated with higher maternal IQ (r=0·44; p<0·0001), older gestational age (r=0·14; p=0·0319), and periconceptional folate (p=0·0002 [t test]). Mean IQ for children whose mothers used periconceptional folate was 108 (95% CI 106-111) compared with 101 (98-104) for children of mothers who did not use periconceptional folate (fi gure 3); dosedependent eff ects were present (appendix p 7).
Appendix pp 8-9 shows results for mixed-model analysis with repeated measures with child IQ at 2 years, 3 years, 4·5 years, and 6 years as dependent variables. Maternal IQ, age at testing, antiepileptic drug, dose, periconceptional folate, gestational age, and maternal age were signifi cant. Appendix p 6 shows adjusted mean cognitive scores (BSID and DAS IQ) and percentages of children who were cognitively impaired (IQ<70 and IQ<80) for all antiepileptic drugs across ages. Cognitive scores improved as children aged (appendix p 13), and percentages of cognitively impaired children decreased (appendix p 6). This improvement did not diff er by antiepileptic drug type. IQ was worse for valproate at ages 3 years, 4·5 years, and 6 years, but the BSID score did not diff er statistically for the smaller sample at age 2 years. Table 3 and appendix p 10 show verbal and non-verbal index score results at age 6 years. Children in the valproate group had signifi cantly lower verbal functioning than did those in the other three antiepileptic drug groups, and did signifi cantly worse on the non-verbal index than did those in the lamotrigine group. Table 4 and appendix p 11 show the results for children aged 6 years of the general memory index of the children's memory scale, the NEPSY executive index, and the BRIEF parent index. Valproate general memory index scores were signifi cantly lower than those in the other three antiepileptic drugs, and executive index scores were worse for valproate than lamotrigine.
Only valproate dose correlated with worse performance for the verbal index (r=-0·40, p=0·0045) and non-verbal index (r=-0·42, p=0·0028), general memory index (r=-0·30, p=0·0434), NEPSY executive index (r=-0·42, p=0·0004), and BRIEF parent index (r=0·35, p=0·0212 [higher score is worse for BRIEF]). No other antiepileptic drug had dose-dependent eff ects. Table 5 shows the means (CIs) and analyses for median dose split. Highdose valproate diff ered from all other groups. 11 and phonological processing, comprehension of instructions and sentence repetition subtests of the developmental neuropsychological assessment. 10 ‡Non-verbal index was created by averaging the standard scores from the pattern construction, matrices, and recall of designs subtests of the diff erential abilities scales, 6 the arrows subtest from the developmental neuropsychological assessment, 10 and the developmental test of visual motor integration. 12 8 shows general memory functioning and is generated by combining the immediate and delayed verbal and visual indexes; means were adjusted for maternal IQ, dose, maternal age, and alcohol use. †The executive index was created by averaging the standard scores from the tower, verbal fl uency, and visual attention subtests from the developmental neuropsychological assessment; 10 means were adjusted for maternal IQ, gestational age, and maternal age. ‡The parent index from the BRIEF 9 measures global executive functions as rated by the child's parent; thus, it incorporates all eight clinical scales (notably, by contrast with the other measures, a higher score on the BRIEF shows worse function); means are adjusted for dose. Verbal and non-verbal indices were equal in a normative sample, but verbal abilities were signifi cantly lower than non-verbal abilities for lamotrigine (p=0·0280) and valproate (p=0·0063). In the normative sample of children from the Wechsler intelligence scale for children IV, 15 173 (93%) of 187 children were right-handed, which is greater than was noted for children in this study (185 [86%] of 215 were right-handed; p=0·0404) with a logistic regression analysis. This diff erence was due to diff erences in the lamotrigine group (59 [83%] of 71 were righthanded; p=0·0287) and valproate group (38 [79%] of 48 were right-handed; p=0·0089). Right-handed frequency was lower for valproate than carbamazepine (54 [93%] of 58 were right-handed; p=0·0284), but not statistically lower than for phenytoin (34 [89%] of 38; p=0·0641). All antiepileptic drugs had higher mean doses for non-right versus right-handers, and a signifi cant dose eff ect was present for all antiepileptic drugs combined (p=0·0329).
Verbal index* † Non-verbal index* ‡ Non-verbal minus verbal*
Our forest plot of propensity score subgroups (appendix p 12) suggests that results were not attributable to diff erences in baseline variables related to child IQ or chances of valproate treatment. In each propensity score subgroup, mean IQ for valproate was lower than mean IQs for other antiepileptic drugs. The forest plot displaying means by seizure type and antiepileptic drug group suggested that antiepileptic drug group diff erences cannot be explained by seizure type imbalances (appendix p 14). Patterns in these plots imply that baseline diff erences do not explain valproate's association with poor IQ outcome. The total-enrolled versus age-6-completer analyses examining sensitivity of results to missing data suggest that the results cannot be explained by incomplete data.
Discussion
Similar to our fi ndings in children aged 3 years and 4·5 years, 3, 16 children with fetal exposure to valproate had reduced IQ (7-10 points) at 6 years compared with other commonly used antiepileptic drugs (ie, carbamazepine, lamotrigine, and phenytoin). Valproate exposure was also associated with worse verbal and memory abilities compared with the other antiepileptic drugs, and worsened non-verbal and executive functions compared with lamotrigine. Teratogens act in a dose-dependent manner and according to genetic susceptibility. An increased valproate dose was associated with reduced IQ, verbal, non-verbal, memory, and executive function, but other antiepileptic drugs had no dose eff ects. Thus, fetal exposure to valproate is associated with a range of cognitive defi cits.
Outcomes in children exposed to low-dose valproate (<1000 mg per day) did not diff er from those in children exposed to the other low or high dose antiepileptic drugs; however, sample sizes might have restricted delineation of diff erences. For example, low-dose valproate (<700 mg per day) had an increased risk for major malformation compared with low-dose lamotrigine (<300 mg per day). 17 Studies in animals suggest that apoptotic eff ects of valproate on the immature brain begin below typical therapeutic doses. 18 Thus, a safe dose of valproate is unknown.
One limitation of this study was the number of participants lost to follow-up. However, cognitive testing was available for at least one age in 279 (90%) of 311 children. Because age-6 IQ is correlated strongly to earlier cognitive outcomes, these data help compensate for children lost to follow-up. The relation of earlier outcomes to age-6 IQ might allow for early detection and intervention.
IQ scores improved with age. Practice eff ects might have contributed to this improvement, and improvements might also be related to intervention programmes. Families were provided results at each test age and assisted in referral to intervention programmes if indicated. Another limitation was that data for intervention programme enrolment were not collected systematically. The eff ects of practice and intervention programmes might have reduced the apparent eff ects of fetal exposure to antiepileptic drugs. The absence of a healthy control group was a further limitation. However, the 7-10 IQ point reduction for valproate compared with other antiepileptic drugs is clinically signifi cant even if the mean valproate IQ was in the normal range.
Verbal and non-verbal indexes were reported as standard scores, so they should be equivalent in the absence of selective eff ects. However, verbal scores were lower than non-verbal scores for lamotrigine and valproate. Practice eff ects might diff erentially aff ect verbal versus non-verbal scores, but this explanation seems unlikely in view of the small practice eff ects for DAS verbal and non-verbal cluster scores. 6 Furthermore, the diff erence was present on the fi rst exposure to DAS at 3 years of age, and the diff erence decreased from 3-6 years of age with repeated testing. This fi nding is also consistent with other studies that have reported verbal impairments associated with fetal valproate exposure [19] [20] [21] and impaired language in children with fetal antiepileptic drug exposure. 22 Typical functional brain asymmetries include left cerebral dominance for language and handedness. The development of these asymmetries can be changed by environmental factors during early neural development. 23 Atypical lateralisation is increased in various developmental disorders including fetal alcohol syndrome. 23 The relatively lower verbal versus non-verbal performances and the reduced frequency of righthandedness in the lamotrigine and valproate groups suggest that fetal exposure to some antiepileptic drugs might aff ect normal cerebral lateralisation. However, our study was limited because we did not assess family handedness or directly measure brain lateralisation.
Other factors related to child IQ in our study include higher maternal IQ and older gestational age. However, maternal IQ was not related to child IQ for the valproate group, although it was for each of the other antiepileptic drug groups, suggesting valproate exposure disrupts this otherwise strong association.
Maternal periconceptional folate was associated with higher age-6 IQ. This fi nding should be interpreted with caution because periconceptional folate was one of several confounding variables, and was established by retrospective maternal interview. The US Public Health Service and Center for Disease Control and Prevention recommend that all women of childbearing age consume 0·4 mg folate daily to prevent birth defects (ie, spina bifi da). 24 Folate is important for normal fetal development, and severe defi ciency or inborn errors of folate metabolism can result in mental retardation. 25 Folate defi ciency can lead to fetal neuronal apoptosis and reduced neuronal progenitor cells. 26 A study of maternal folate status later in pregnancy and one older periconceptional folate study found no relation with cognitive outcome, but seven recent studies have reported positive associations of periconceptional folate with neurodevelopmental outcomes (appendix pp [15] [16] . 27, 28 Thus, our fi nding adds to the evidence that periconceptional folate might have benefi cial eff ects on cognitive development.
Strengths of this study are our prospective design, use of masked cognitive assessments with standardised measures, and detailed monitoring of multiple potential confounding factors. Limitations are its relatively small non-population-based sample, loss to follow-up, nonrandomisation, inadequate pharmacokinetics, and no unexposed controls. Detection of dose eff ects for nonvalproate antiepileptic drugs might require larger sample sizes as noted for malformations associated with carbamazepine, lamotrigine, and phenobarbital. 17 Antiepileptic drug clearance is variable during pregnancy; 29 future studies should measure antiepileptic drug levels to better assess intrauterine exposure. Randomised pregnancy trials of antiepileptic drugs are not possible, and observational studies might be confounded by diff erences in baseline characteristics (eg, maternal IQ, dose, ethnic group, or epilepsy type). Our analyses suggest that these baseline group diff erences do not explain our fi ndings, but some residual confounding eff ects are possible. Thus, observational studies require replication.
Most women with epilepsy cannot avoid use of antiepileptic drugs during pregnancy because of the risks from seizures to both mother and child. Based on anatomical and cognitive risks, 2,3 we propose that valproate is a poor fi rst-choice antiepileptic drug for most women of childbearing potential. However, a few women with generalised epilepsy can only be controlled by valproate.
Many gaps exist in our knowledge about epilepsy care during preconception and pregnancy. 2 The mechanisms underlying observed defi cits are uncertain, but antiepileptic drugs might aff ect fetal neurodevelopment via neuronal apoptosis induced by antiepileptic drugs, reduced neurotrophin expression, decreased neuronal survival-promoting proteins, reduced neurogenesis, or impaired physiology in remaining neurons. 18 Many antiepileptic drugs are untested in animal models and have not been assessed in clinical cohorts. Additional research is needed to confi rm our fi ndings and to improve our knowledge for care in this population. In conclusion, we noted that fetal valproate exposure has dose-dependent associations with reduced cognitive abilities across a range of domains at 6 years of age. Women requiring an antiepileptic drug and their clinicians should be aware of these fi ndings in choosing their treatment (panel).
Panel: Research in context
Systematic review
We examined the American Academy of Neurology evidence-based review, 2 a systematic review from 2012, 30 and pertinent articles listed in these sources. We also searched PubMed to identify articles related to eff ects of periconceptional folate on cognition and antiepileptic drug eff ects on cognition and cerebral lateralisation. Additional studies are listed in the appendix.
Interpretation
The Neurodevelopmental Eff ects of Antiepileptic Drugs (NEAD) study is the largest prospective investigation of cognitive outcomes after fetal exposure for carbamazepine, lamotrigine, phenytoin, and valproate monotherapies. Neuropsychological assessments in almost all previous studies were restricted to intelligence quotient (IQ) or a developmental measure. Most did not control for maternal IQ, which is the major predictor of child IQ, 5 and many did not prospectively collect other important potential confounding factors. The NEAD study provides the most detailed neuropsychological assessment, prospectively collecting a large array of factors, including maternal IQ. To our knowledge, NEAD is the fi rst study to show that fetal valproate exposure has dose-dependent associations with reduced cognitive abilities across many domains, show longitudinal changes in intelligence across ages 2-6 years, and show reduced right-handedness. The verbal and non-verbal asymmetries match the fi ndings of atypical handedness providing support for our hypothesis that fetal exposure to some antiepileptic drugs might alter cerebral lateralisation. The positive association of periconceptional folate with IQ is the fi rst reported in children of mothers with epilepsy and is consistent with other recent studies, but requires replication.
